Meeting
2013 ASCO Annual Meeting
4EVER: Assessment of circulating tumor cells with a novel, filtration-based method, in a phase IIIb multicenter study for postmenopausal, HER2-negative, estrogen receptor-positive, advanced breast cancer patients.
Authors
Peter A. Fasching
Department of Obstetrics and Gynecology, University Erlangen, Erlangen, Germany
Peter A. Fasching , Walter Gumbrecht , Tanja N Fehm , Lothar Haeberle , Mathias Muth , Daniel Sickert , Michael Pugia , Katja Friedrich , Mark Matzas , Diana Lueftner , Matthias W. Beckmann , Peyman Hadji , Julia Kreuzeder , Michael P Lux , Wolfgang Janni , Andreas Schneeweiss , Erik Belleville , Thomas Decker , Eva-Maria Grischke , Hans Tesch
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer - HER2/ER
Track
Breast Cancer
Sub Track
ER+
Clinical Trial Registration Number
NCT01626222
Citation
J Clin Oncol 31, 2013 (suppl; abstr 591)
DOI
10.1200/jco.2013.31.15_suppl.591
Abstract #
591
Poster Bd #
7F
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
XENERA-1: A phase II trial of xentuzumab (Xe) in combination with everolimus (Ev) and exemestane (Ex) in patients with hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer (mBC) and non-visceral involvement.
First Author: Peter Schmid
Poster
2013 Breast Cancer Symposium
Correlation of molecular alterations with efficacy of everolimus in hormone-receptor–positive, HER2-negative advanced breast cancer: Results from BOLERO-2.
First Author: Hope S. Rugo
Poster
2013 ASCO Annual Meeting
BOLERO-6: Phase II study of everolimus plus exemestane versus everolimus or capecitabine monotherapy in HR+ HER2- advanced breast cancer.
First Author: Bent Ejlertsen
Poster
2011 ASCO Annual Meeting
Bosutinib and exemestane (EXE) versus EXE alone in postmenopausal (postm) women with hormone receptor–positive (HR+) HER2-negative (HER2–) advanced breast cancer (ABC).
First Author: B. Moy